Scinai Immunotherapeutics (SCNI) Cash from Operations Growth (3y) (2021 - 2026)

Scinai Immunotherapeutics (SCNI) Cash from Operations Growth (3y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -5.07%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 33.08%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -7.60%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Scinai Immunotherapeutics 3.74 Bn 624.08 Mn -1.12 Mn 21.92%

Historic Data

Download Data
DateValue
Mar 31, 2026 21.92%
Jun 30, 2025 25.20%
Mar 31, 2025 1.97%
Dec 31, 2024 16.72%
Sep 30, 2024 30.94%
Jun 30, 2024 39.43%
Mar 31, 2024 -8.04%
Dec 31, 2023 57.45%
Sep 30, 2023 40.05%
Jun 30, 2023 37.60%
Mar 31, 2022 32.80%
Mar 31, 2021 23.33%